Long noncoding RNA GHET1 promotes the development of bladder cancer.
In spite of the advances in the diagnosis and treatment of bladder cancer, the prognosis of bladder cancer remains relatively poor. As a result, it is vital to identify novel diagnostic and prognostic marker of bladder cancer. A growing volume of literature has implicated the vital role of long noncoding RNA in the development of cancer. GHET1, a recently identified lncRNA, was initially characterized in gastric cancer. However, its role in bladder cancer remains largely unknown. In this study, we demonstrated that GHET1 was upregulated in bladder cancer tissues compared to adjacent normal tissues and its over-expression correlates with tumor size, advanced tumor and lymph node status, and poor survival. GHET1 knockdown suppressed the proliferation and invasion of bladder cancer cells in vitro. In the meantime, inhibition of GHET1 reversed the epithelial-mesenchymal-transition in bladder cancer cell line. Taken together, our study suggests that the potential use of GHET1 as a prognostic marker and therapeutic target of bladder cancer.
Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital) Wenzhou, China.
Lin-Jin
LJ
Li
Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital) Wenzhou, China.
Jian-Long
JL
Zhu
Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital) Wenzhou, China.
Wen-Shuo
WS
Bao
Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital) Wenzhou, China.
Da-Ke
DK
Chen
Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University (Wenzhou People's Hospital) Wenzhou, China.
Wei-Wen
WW
Huang
Department of Urology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou, China.
Zhi-Liang
ZL
Weng
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D034622:RNA Interference; D062085:RNA, Long Noncoding / Q000235:genetics* / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D047368:Tumor Burden; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology
D014408:Biomarkers, Tumor; C587667:GHET1 transcript, human; D062085:RNA, Long Noncoding
GHET1; Long noncoding RNA; bladder cancer; epithelial-mesenchymal-transition; prognosis; proliferation